MBOT vs. SSKN, UTRS, OSA, ICU, TTOO, MDAI, VAPO, NXGL, FEMY, and VERO
Should you be buying Microbot Medical stock or one of its competitors? The main competitors of Microbot Medical include STRATA Skin Sciences (SSKN), Minerva Surgical (UTRS), ProSomnus (OSA), SeaStar Medical (ICU), T2 Biosystems (TTOO), Spectral AI (MDAI), Vapotherm (VAPO), NEXGEL (NXGL), Femasys (FEMY), and Venus Concept (VERO). These companies are all part of the "surgical & medical instruments" industry.
STRATA Skin Sciences (NASDAQ:SSKN) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations.
Microbot Medical has a net margin of 0.00% compared to Microbot Medical's net margin of -20.40%. Microbot Medical's return on equity of -38.76% beat STRATA Skin Sciences' return on equity.
STRATA Skin Sciences presently has a consensus target price of $3.80, indicating a potential upside of 590.41%. Microbot Medical has a consensus target price of $8.00, indicating a potential upside of 540.00%. Given Microbot Medical's higher possible upside, research analysts plainly believe STRATA Skin Sciences is more favorable than Microbot Medical.
In the previous week, STRATA Skin Sciences and STRATA Skin Sciences both had 2 articles in the media. Microbot Medical's average media sentiment score of 1.43 beat STRATA Skin Sciences' score of 0.63 indicating that STRATA Skin Sciences is being referred to more favorably in the media.
STRATA Skin Sciences has higher revenue and earnings than Microbot Medical. STRATA Skin Sciences is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
Microbot Medical received 122 more outperform votes than STRATA Skin Sciences when rated by MarketBeat users. Likewise, 70.55% of users gave Microbot Medical an outperform vote while only 63.90% of users gave STRATA Skin Sciences an outperform vote.
STRATA Skin Sciences has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 3.14, meaning that its stock price is 214% more volatile than the S&P 500.
47.5% of STRATA Skin Sciences shares are owned by institutional investors. Comparatively, 15.2% of Microbot Medical shares are owned by institutional investors. 40.4% of STRATA Skin Sciences shares are owned by company insiders. Comparatively, 10.6% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
STRATA Skin Sciences beats Microbot Medical on 9 of the 15 factors compared between the two stocks.
Get Microbot Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBOT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Microbot Medical Competitors List
Related Companies and Tools